nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—ABCB1—HIF-1-alpha transcription factor network—EP300—ocular cancer	0.00195	0.00195	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—SAG—ocular cancer	0.00191	0.00191	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—ocular cancer	0.00187	0.00187	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—GNAQ—ocular cancer	0.00184	0.00184	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—SAG—ocular cancer	0.00183	0.00183	CbGpPWpGaD
Paroxetine—SLC6A3—NRF2 pathway—TGFB1—ocular cancer	0.0018	0.0018	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—E2F1—ocular cancer	0.00172	0.00172	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—GNA11—ocular cancer	0.00169	0.00169	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—E2F5—ocular cancer	0.00169	0.00169	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PSPH—ocular cancer	0.00169	0.00169	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—E2F4—ocular cancer	0.00166	0.00166	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—HDAC1—ocular cancer	0.00166	0.00166	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—RBL1—ocular cancer	0.00162	0.00162	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—GNA11—ocular cancer	0.00162	0.00162	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—E2F5—ocular cancer	0.00162	0.00162	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—E2F4—ocular cancer	0.00159	0.00159	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—GNAQ—ocular cancer	0.00157	0.00157	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—RBL1—ocular cancer	0.00156	0.00156	CbGpPWpGaD
Paroxetine—HTR2A—SIDS Susceptibility Pathways—EP300—ocular cancer	0.00155	0.00155	CbGpPWpGaD
Paroxetine—SLC6A3—Neuronal System—MDM2—ocular cancer	0.00154	0.00154	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—GNA11—ocular cancer	0.00154	0.00154	CbGpPWpGaD
Paroxetine—CHRM2—SIDS Susceptibility Pathways—EP300—ocular cancer	0.00153	0.00153	CbGpPWpGaD
Paroxetine—SLC6A4—Circadian rythm related genes—TP53—ocular cancer	0.00151	0.00151	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—GNAQ—ocular cancer	0.00151	0.00151	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—CDKN2B—ocular cancer	0.00148	0.00148	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK2—ocular cancer	0.00148	0.00148	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—GNA11—ocular cancer	0.00147	0.00147	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PSPH—ocular cancer	0.00147	0.00147	CbGpPWpGaD
Paroxetine—ABCB1—Allograft Rejection—TGFB1—ocular cancer	0.00146	0.00146	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—GNAQ—ocular cancer	0.00143	0.00143	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—E2F3—ocular cancer	0.00141	0.00141	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—ocular cancer	0.0014	0.0014	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PSPH—ocular cancer	0.00139	0.00139	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PSPH—ocular cancer	0.00137	0.00137	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—GNAQ—ocular cancer	0.00137	0.00137	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—E2F1—ocular cancer	0.00136	0.00136	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—E2F3—ocular cancer	0.00135	0.00135	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TFDP1—ocular cancer	0.00131	0.00131	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SAG—ocular cancer	0.0013	0.0013	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SAG—ocular cancer	0.00129	0.00129	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SAG—ocular cancer	0.00128	0.00128	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SAG—ocular cancer	0.00127	0.00127	CbGpPWpGaD
Paroxetine—CHRM1—Circadian rythm related genes—EP300—ocular cancer	0.00126	0.00126	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TFDP1—ocular cancer	0.00125	0.00125	CbGpPWpGaD
Paroxetine—ABCB1—HIF-1-alpha transcription factor network—AKT1—ocular cancer	0.00118	0.00118	CbGpPWpGaD
Paroxetine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—ocular cancer	0.00116	0.00116	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—GNA11—ocular cancer	0.00115	0.00115	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—E2F5—ocular cancer	0.00115	0.00115	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—GNA11—ocular cancer	0.00114	0.00114	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—E2F5—ocular cancer	0.00114	0.00114	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—GNA11—ocular cancer	0.00114	0.00114	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—E2F5—ocular cancer	0.00114	0.00114	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—GNA11—ocular cancer	0.00113	0.00113	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—E2F5—ocular cancer	0.00113	0.00113	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—E2F4—ocular cancer	0.00112	0.00112	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—E2F4—ocular cancer	0.00112	0.00112	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—E2F4—ocular cancer	0.00111	0.00111	CbGpPWpGaD
Paroxetine—SLC6A3—Transmission across Chemical Synapses—HRAS—ocular cancer	0.0011	0.0011	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—E2F4—ocular cancer	0.0011	0.0011	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—RBL1—ocular cancer	0.0011	0.0011	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—RBL1—ocular cancer	0.0011	0.0011	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—RBL1—ocular cancer	0.00109	0.00109	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—RBL1—ocular cancer	0.00108	0.00108	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—GNAQ—ocular cancer	0.00107	0.00107	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—GNAQ—ocular cancer	0.00106	0.00106	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—GNAQ—ocular cancer	0.00106	0.00106	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—GNAQ—ocular cancer	0.00105	0.00105	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—GNA11—ocular cancer	0.00104	0.00104	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MAML2—ocular cancer	0.00104	0.00104	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—ocular cancer	0.00104	0.00104	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—GNA11—ocular cancer	0.00104	0.00104	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—GNA11—ocular cancer	0.00103	0.00103	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—GNA11—ocular cancer	0.00102	0.00102	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MAML2—ocular cancer	0.000996	0.000996	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—GNAQ—ocular cancer	0.000968	0.000968	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—GNAQ—ocular cancer	0.000963	0.000963	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—GNAQ—ocular cancer	0.00096	0.00096	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—E2F3—ocular cancer	0.000955	0.000955	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—GNAQ—ocular cancer	0.000951	0.000951	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—E2F3—ocular cancer	0.00095	0.00095	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—ocular cancer	0.000947	0.000947	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—E2F3—ocular cancer	0.000947	0.000947	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—E2F3—ocular cancer	0.000937	0.000937	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—GNA11—ocular cancer	0.000908	0.000908	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—ocular cancer	0.000903	0.000903	CbGpPWpGaD
Paroxetine—CHRM1—Circadian rythm related genes—TP53—ocular cancer	0.000903	0.000903	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TFDP1—ocular cancer	0.000888	0.000888	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TFDP1—ocular cancer	0.000883	0.000883	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TFDP1—ocular cancer	0.00088	0.00088	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—ocular cancer	0.000874	0.000874	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TFDP1—ocular cancer	0.000872	0.000872	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—GNA11—ocular cancer	0.000869	0.000869	CbGpPWpGaD
Paroxetine—SLC6A3—Neuronal System—HRAS—ocular cancer	0.000846	0.000846	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—GNAQ—ocular cancer	0.000844	0.000844	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—ocular cancer	0.000832	0.000832	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—MDM2—ocular cancer	0.000824	0.000824	CbGpPWpGaD
Paroxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—ocular cancer	0.000823	0.000823	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—ocular cancer	0.000819	0.000819	CbGpPWpGaD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—ocular cancer	0.000816	0.000816	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—GNAQ—ocular cancer	0.000808	0.000808	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—HRAS—ocular cancer	0.000765	0.000765	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—HDAC1—ocular cancer	0.000761	0.000761	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—CDKN1B—ocular cancer	0.000752	0.000752	CbGpPWpGaD
Paroxetine—TACR1—GPCR downstream signaling—AKT1—ocular cancer	0.000744	0.000744	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—GNA11—ocular cancer	0.00073	0.00073	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—HDAC1—ocular cancer	0.000728	0.000728	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—ocular cancer	0.000725	0.000725	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—ocular cancer	0.000723	0.000723	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—CCND1—ocular cancer	0.000717	0.000717	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MAML2—ocular cancer	0.000705	0.000705	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MAML2—ocular cancer	0.000701	0.000701	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MAML2—ocular cancer	0.000699	0.000699	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—CDKN1A—ocular cancer	0.000694	0.000694	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MAML2—ocular cancer	0.000692	0.000692	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CDKN2B—ocular cancer	0.000682	0.000682	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—GNAQ—ocular cancer	0.000678	0.000678	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—AKT1—ocular cancer	0.000676	0.000676	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—EP300—ocular cancer	0.00066	0.00066	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CDKN2B—ocular cancer	0.000653	0.000653	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—GNA11—ocular cancer	0.000628	0.000628	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—E2F1—ocular cancer	0.000626	0.000626	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—GNA11—ocular cancer	0.000615	0.000615	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—GNA11—ocular cancer	0.000612	0.000612	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—GNA11—ocular cancer	0.00061	0.00061	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—GNA11—ocular cancer	0.000604	0.000604	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—E2F1—ocular cancer	0.000599	0.000599	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ocular cancer	0.000595	0.000595	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—GNAQ—ocular cancer	0.000583	0.000583	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—MYC—ocular cancer	0.000575	0.000575	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—TGFB1—ocular cancer	0.000574	0.000574	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—GNAQ—ocular cancer	0.000572	0.000572	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—GNAQ—ocular cancer	0.000569	0.000569	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—GNAQ—ocular cancer	0.000567	0.000567	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—GNAQ—ocular cancer	0.000562	0.000562	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GNA11—ocular cancer	0.000531	0.000531	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—HDAC1—ocular cancer	0.000516	0.000516	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HDAC1—ocular cancer	0.000513	0.000513	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HDAC1—ocular cancer	0.000511	0.000511	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HDAC1—ocular cancer	0.000506	0.000506	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ocular cancer	0.000503	0.000503	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GNAQ—ocular cancer	0.000494	0.000494	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—TP53—ocular cancer	0.000473	0.000473	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GNA11—ocular cancer	0.000463	0.000463	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CDKN2B—ocular cancer	0.000462	0.000462	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CDKN2B—ocular cancer	0.00046	0.00046	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CDKN2B—ocular cancer	0.000458	0.000458	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CDKN2B—ocular cancer	0.000454	0.000454	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—HRAS—ocular cancer	0.000452	0.000452	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GNA11—ocular cancer	0.000436	0.000436	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GNA11—ocular cancer	0.000432	0.000432	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GNAQ—ocular cancer	0.00043	0.00043	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—E2F1—ocular cancer	0.000424	0.000424	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—E2F1—ocular cancer	0.000422	0.000422	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—E2F1—ocular cancer	0.000421	0.000421	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—E2F1—ocular cancer	0.000417	0.000417	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GNAQ—ocular cancer	0.000406	0.000406	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GNAQ—ocular cancer	0.000402	0.000402	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—AKT1—ocular cancer	0.000399	0.000399	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—EP300—ocular cancer	0.000399	0.000399	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MDM2—ocular cancer	0.000378	0.000378	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MDM2—ocular cancer	0.000362	0.000362	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—HRAS—ocular cancer	0.000351	0.000351	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CDKN1B—ocular cancer	0.000345	0.000345	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—AKT1—ocular cancer	0.000342	0.000342	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—HRAS—ocular cancer	0.000336	0.000336	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CDKN1B—ocular cancer	0.000331	0.000331	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CCND1—ocular cancer	0.000329	0.000329	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—AKT1—ocular cancer	0.000327	0.000327	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—ocular cancer	0.000324	0.000324	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CDKN1A—ocular cancer	0.000319	0.000319	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CCND1—ocular cancer	0.000315	0.000315	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—AKT1—ocular cancer	0.00031	0.00031	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CDKN1A—ocular cancer	0.000305	0.000305	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—EP300—ocular cancer	0.000303	0.000303	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—AKT1—ocular cancer	0.000297	0.000297	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—EP300—ocular cancer	0.00029	0.00029	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MYC—ocular cancer	0.000264	0.000264	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TGFB1—ocular cancer	0.000264	0.000264	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MDM2—ocular cancer	0.000256	0.000256	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MDM2—ocular cancer	0.000255	0.000255	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MDM2—ocular cancer	0.000254	0.000254	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MYC—ocular cancer	0.000253	0.000253	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TGFB1—ocular cancer	0.000252	0.000252	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MDM2—ocular cancer	0.000252	0.000252	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—EP300—ocular cancer	0.000244	0.000244	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—HRAS—ocular cancer	0.000238	0.000238	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—HRAS—ocular cancer	0.000237	0.000237	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—HRAS—ocular cancer	0.000236	0.000236	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CDKN1B—ocular cancer	0.000234	0.000234	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—HRAS—ocular cancer	0.000234	0.000234	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CDKN1B—ocular cancer	0.000233	0.000233	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CDKN1B—ocular cancer	0.000232	0.000232	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—AKT1—ocular cancer	0.000232	0.000232	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—AKT1—ocular cancer	0.00023	0.00023	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CDKN1B—ocular cancer	0.00023	0.00023	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—AKT1—ocular cancer	0.00023	0.00023	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—AKT1—ocular cancer	0.000227	0.000227	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCND1—ocular cancer	0.000223	0.000223	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCND1—ocular cancer	0.000222	0.000222	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCND1—ocular cancer	0.000221	0.000221	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCND1—ocular cancer	0.000219	0.000219	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TP53—ocular cancer	0.000217	0.000217	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CDKN1A—ocular cancer	0.000216	0.000216	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CDKN1A—ocular cancer	0.000215	0.000215	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CDKN1A—ocular cancer	0.000214	0.000214	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CDKN1A—ocular cancer	0.000212	0.000212	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—AKT1—ocular cancer	0.00021	0.00021	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—EP300—ocular cancer	0.00021	0.00021	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—AKT1—ocular cancer	0.000209	0.000209	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—AKT1—ocular cancer	0.000208	0.000208	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TP53—ocular cancer	0.000208	0.000208	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—HRAS—ocular cancer	0.000208	0.000208	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—AKT1—ocular cancer	0.000206	0.000206	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—EP300—ocular cancer	0.000206	0.000206	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—EP300—ocular cancer	0.000204	0.000204	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—EP300—ocular cancer	0.000204	0.000204	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—EP300—ocular cancer	0.000202	0.000202	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—HRAS—ocular cancer	0.000199	0.000199	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—AKT1—ocular cancer	0.000183	0.000183	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MYC—ocular cancer	0.000179	0.000179	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TGFB1—ocular cancer	0.000179	0.000179	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MYC—ocular cancer	0.000178	0.000178	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TGFB1—ocular cancer	0.000178	0.000178	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MYC—ocular cancer	0.000178	0.000178	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—EP300—ocular cancer	0.000178	0.000178	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TGFB1—ocular cancer	0.000177	0.000177	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MYC—ocular cancer	0.000176	0.000176	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—AKT1—ocular cancer	0.000175	0.000175	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TGFB1—ocular cancer	0.000175	0.000175	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—EP300—ocular cancer	0.000155	0.000155	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—AKT1—ocular cancer	0.000147	0.000147	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TP53—ocular cancer	0.000147	0.000147	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TP53—ocular cancer	0.000146	0.000146	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TP53—ocular cancer	0.000146	0.000146	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—EP300—ocular cancer	0.000146	0.000146	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—EP300—ocular cancer	0.000144	0.000144	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TP53—ocular cancer	0.000144	0.000144	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—HRAS—ocular cancer	0.000141	0.000141	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HRAS—ocular cancer	0.00014	0.00014	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HRAS—ocular cancer	0.000139	0.000139	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HRAS—ocular cancer	0.000138	0.000138	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—AKT1—ocular cancer	0.000127	0.000127	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AKT1—ocular cancer	0.000124	0.000124	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AKT1—ocular cancer	0.000124	0.000124	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AKT1—ocular cancer	0.000123	0.000123	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AKT1—ocular cancer	0.000122	0.000122	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—AKT1—ocular cancer	0.000107	0.000107	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—AKT1—ocular cancer	9.35e-05	9.35e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AKT1—ocular cancer	8.81e-05	8.81e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AKT1—ocular cancer	8.73e-05	8.73e-05	CbGpPWpGaD
